Cargando…

Loss of CENP-I Impairs Homologous Recombination and Sensitizes Cells to PARP1 Inhibition

SIMPLE SUMMARY: Centromere Protein I (CENP-I) is one of a family of cellular molecules that is essential for the separation of chromosomes during mitosis and mitotic progression. Interestingly, other CENP family proteins, such as CENP-A, have been shown to be involved in double-strand break repair....

Descripción completa

Detalles Bibliográficos
Autores principales:	Dang, Tuyen T., Morales, Julio C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267748/ https://www.ncbi.nlm.nih.gov/pubmed/34206916 http://dx.doi.org/10.3390/cancers13133202

Ejemplares similares

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer
por: Yadav, Anjali, et al.
Publicado: (2023)

WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors
por: Burdova, Kamila, et al.
Publicado: (2019)

Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
por: Wang, Zhihai, et al.
Publicado: (2019)

Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors
por: Wang, Junhui, et al.
Publicado: (2015)

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer
por: Dillon, Kasia M., et al.
Publicado: (2022)

ID3 promotes homologous recombination via non-transcriptional and transcriptional mechanisms and its loss confers sensitivity to PARP inhibition
por: Bakr, Ali, et al.
Publicado: (2021)

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
por: Amin, Oreekha, et al.
Publicado: (2015)

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
por: von Werdt, Alexander, et al.
Publicado: (2021)

Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition
por: Hou, Dong, et al.
Publicado: (2017)

Correction to ‘ID3 promotes homologous recombination via non-transcriptional and transcriptional mechanisms and its loss confers sensitivity to PARP inhibition’
Publicado: (2023)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
por: Xu, Junfen, et al.
Publicado: (2021)

PARP1 suppresses homologous recombination events in mice in vivo
por: Claybon, Alison, et al.
Publicado: (2010)

SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair
por: Lin, Shengbin, et al.
Publicado: (2022)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Methylated-UHRF1 and PARP1 interaction is critical for homologous recombination
por: Hahm, Ja Young, et al.
Publicado: (2020)

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
por: Yin, Chao, et al.
Publicado: (2022)

Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality
por: Sanese, Paola, et al.
Publicado: (2020)

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
por: Póti, Ádám, et al.
Publicado: (2019)

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
por: Nacson, Joseph, et al.
Publicado: (2018)

CENP-C and CENP-I are key connecting factors for kinetochore and CENP-A assembly
por: Shono, Nobuaki, et al.
Publicado: (2015)

SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2019)

Tetraploidy‐linked sensitization to CENP‐E inhibition in human cells
por: Yoshizawa, Koya, et al.
Publicado: (2023)

PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response
por: Wurster, Stephanie, et al.
Publicado: (2016)

Breaking the Iron Homeostasis: A “Trojan Horse” Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition
por: Li, Yangyang, et al.
Publicado: (2022)

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
por: Yazinski, Stephanie A., et al.
Publicado: (2017)

PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
por: Sugimura, Kazuto, et al.
Publicado: (2008)

hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors
por: Gundogdu, Ramazan, et al.
Publicado: (2021)

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
por: Verma, Priyanka, et al.
Publicado: (2021)

Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
por: Chopra, Neha, et al.
Publicado: (2020)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019)

Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer
por: Ozden, Ozkan, et al.
Publicado: (2016)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
por: Gu, Yayun, et al.
Publicado: (2021)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers
por: Janysek, Dawn C., et al.
Publicado: (2021)

PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components
por: O’Sullivan Coyne, Geraldine, et al.
Publicado: (2022)

Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
por: Pai Bellare, Ganesh, et al.
Publicado: (2021)

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
por: Pawlyn, Charlotte, et al.
Publicado: (2018)

PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
por: Beck, Carole, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8mtm87i3qqg7c1h4is8g83c21s